Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670678 | 0.88 | CHRNA7 (0.67) | CHRNA7TP53GAAMAPTTRPV1 | |
| SCHEMBL29776952 | 0.87 | CHRNA7 (0.76) | CHRNA7TP53GAAMAPTTRPV1 | |
| SCHEMBL20472469 | 0.87 | CHRNA7 (0.76) | CHRNA7TP53GAAMAPTTRPV1 | |
| SCHEMBL4349059 | 0.86 | GRIK1 (0.63) | CHRNA7MAPTTRPV1MEN1KMT2A | |
| SCHEMBL3681047 | 0.86 | CHRNA7 (0.67) | CHRNA7TP53GAAMAPTTRPV1 | |
| SCHEMBL1459621 | 0.84 | CHRNA7 (1.00) | CHRNA7TP53GAAMAPTTRPV1 | |
| SCHEMBL6417211 | 0.83 | CHRNA7 (0.63) | CHRNA7TRPV1MEN1KMT2AALDH1A1 | |
| SCHEMBL5594738 | 0.82 | CHRNA7 (0.66) | CHRNA7TP53GAAMAPTTRPV1 | |
| SCHEMBL4350084 | 0.80 | MTOR (0.56) | CHRNA7TRPV1MEN1KMT2ACYP1A2 | |
| SCHEMBL6229028 | 0.79 | MTOR (0.56) | CHRNA7MAPTTRPV1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | US | claimed |
| US-20070142450-A1 | Novel urea derivatives and their medical use | NEUROSEARCH A/S (DK) | 2007-06-21 | — | — | US | claimed |
| EP-2255848-A2 | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | NeuroSearch AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20070142450-A1 | Novel urea derivatives and their medical use | NEUROSEARCH A/S (DK) | 2007-06-21 | — | — | US | disclosed |
| US-20070142450-A1 | Novel urea derivatives and their medical use | NEUROSEARCH A/S (DK) | 2007-06-21 | — | — | US | disclosed |
| US-20070142450-A1 | Novel urea derivatives and their medical use | NEUROSEARCH A/S (DK) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | CHRNA10, CHRNA4, CHRNA5 | CHRNA7 7/4885TP53 2042/4885GAA 559/4885 |
| US-20070142450-A1 | Novel urea derivatives and their medical use | ACHE, NMUR1, NMUR2 | CHRNA7 11/4885TP53 4506/4885GAA 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.